Abstract
Abstract Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myelo...
Cite
CITATION STYLE
APA
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., … Usmani, S. Z. (2022). Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 387(6), 495–505. https://doi.org/10.1056/nejmoa2203478
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free